---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336691"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-08-06T11:05:06+00:00"
generated_at: "2026-08-06T11:10:21.623811+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viridian reports Q2 net loss of $127M; Lumvoa FDA-approved and launched in June

## Summary
- Lumvoa (veligrotug-vvze) approved by FDA for thyroid eye disease on June 26, 2026, and immediately launched in U.S.
- Elegrobart BLA submission on track for Q1 2027; phase 3 trials showed robust proptosis reduction.
- Cash, cash equivalents, and marketable securities of $981.5M as of June 30, 2026, up from $762.2M at March 31, 2026.
- Net loss for Q2 2026 was $127.1M, compared to $100.7M in Q2 2025; R&D expenses decreased to $71.6M from $86.6M.
- Completed convertible debt and equity financing in May 2026 with gross proceeds of $394M.

## SEC filing metadata
- accession: 0001193125-26-336691
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-08-06T11:05:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/0001193125-26-336691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336691
- JSON: https://secwatch.observer/filing/0001193125-26-336691.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.